Production of MPS VII mouse (Gustm(hE540Amiddle dotmE536A)Sly) doubly tolerant to human and mouse beta-glucuronidase
Open Access
- 1 May 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 12 (9) , 961-973
- https://doi.org/10.1093/hmg/ddg119
Abstract
Mucopolysaccharidosis VII (MPS VII, Sly syndrome) is an autosomal recessive lysosomal storage disease caused by β-glucuronidase (GUS) deficiency. A naturally occurring mouse model of that disease has been very useful for studying experimental approaches to therapy. However, immune responses can complicate evaluation of the long-term benefits of enzyme replacement or gene therapy delivered to adult MPS VII mice. To make this model useful for studying the long-term effectiveness and side effects of experimental therapies delivered to adult mice, we developed a new MPS VII mouse model, which is tolerant to both human and murine GUS. To achieve this, we used homologous recombination to introduce simultaneously a human cDNA transgene expressing inactive human GUS into intron 9 of the murine Gus gene and a targeted active site mutation (E536A) into the adjacent exon 10. When the heterozygote products of germline transmission were bred to homozygosity, the homozygous mice expressed no GUS enzyme activity but expressed inactive human GUS protein highly and were tolerant to immune challenge with human enzyme. Expression of the mutant murine Gus gene was reduced to about 10% of normal levels, but the inactive murine GUS enzyme also conferred tolerance to murine GUS. This MPS VII mouse model should be useful to evaluate therapeutic responses in adult mice receiving repetitive doses of enzyme or mice receiving gene therapy as adults. Heterozygotes expressed only 9.5–26% of wild-type levels of murine GUS instead of the expected 50%, indicating a dominant-negative effect of the mutant enzyme monomers on the activity of GUS tetramers in different tissues. Corrective gene therapy in this model should provide high enough levels of expression of normal GUS monomers to overcome the dominant negative effect of mutant monomers on newly synthesized GUS tetramers in most tissues.Keywords
This publication has 57 references indexed in Scilit:
- Treatment of murine mucopolysaccharidosis type VII by syngeneic bone marrow transplantation in neonates.1993
- Simultaneous Preparation and Quantitation of Proteoglycans by Precipitation with Alcian BlueAnalytical Biochemistry, 1993
- Mutational analysis of a patient with mucopolysaccharidosis type VII, and identification of pseudogenes.1993
- Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transferNature, 1992
- Increased life span and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation.1991
- Mucopolysaccharidosis type VII: characterization of mutations and molecular heterogeneity.1991
- Molecular basis of mucopolysaccharidosis type VII: replacement of Ala619 in β-glucuronidase with ValGene, 1990
- A MURINE MODEL OF MUCOPOLYSACCHARIDOSIS-VII - GROSS AND MICROSCOPIC FINDINGS IN BETA-GLUCURONIDASE-DEFICIENT MICE1990
- Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency.Journal of Clinical Investigation, 1989
- Mammalian β-Glucuronidase: Genetics, Molecular Biology, and Cell BiologyPublished by Elsevier ,1989